Worldwide presence

English
français

Media

MMMM D, YYYY

Press Releases 2019

Home
Media
Press releases
2019

Press Releases - 2019

Facebook
Twitter
LinkedIn

Download the PDF version
2019-08-06MMMM DD YYYY
Press releases
Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
Download the PDF version
2019-08-06MMMM DD YYYY
Press releases
Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis
Download the PDF version
2019-07-29MMMM DD YYYY
Press releases
Sanofi : Online Availability of Sanofi Group’s Half-Year Financial Report for 2019
Download the PDF version
2019-07-29MMMM DD YYYY
Press releases
Sanofi delivered solid growth in Q2 2019
Download the PDF version
2019-07-26MMMM DD YYYY
Press releases
Sanofi : Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon
Download the PDF version
2019-07-26MMMM DD YYYY
Press releases
Sanofi : Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer
Download the PDF version
2019-07-23MMMM DD YYYY
Press releases
Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care
Download the PDF version
2019-07-10MMMM DD YYYY
Press releases
Sanofi : FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
Download the PDF version
2019-07-02MMMM DD YYYY
Press releases
Sanofi : Availability of the Pre-quarterly Results Communication
Download the PDF version
2019-07-01MMMM DD YYYY
Press releases
Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union
Download the PDF version
2019-06-28MMMM DD YYYY
Press releases
Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
Download the PDF version
2019-06-27MMMM DD YYYY
Press releases
Sanofi : FDA to review MenQuadfi, a meningococcal vaccine candidate
Download the PDF version
2019-06-26MMMM DD YYYY
Press releases
Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
Download the PDF version
2019-06-21MMMM DD YYYY
Press releases
Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma
Download the PDF version
2019-06-18MMMM DD YYYY
Press releases
Sanofi and Google to develop new healthcare Innovation Lab
Download the PDF version
2019-06-09MMMM DD YYYY
Press releases
Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments
Download the PDF version
2019-06-07MMMM DD YYYY
Press releases
Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer
Download the PDF version
2019-06-02MMMM DD YYYY
Press releases
Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma
Download the PDF version
2019-05-07MMMM DD YYYY
Press releases
Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
Download the PDF version
2019-04-30MMMM DD YYYY
Press releases
Sanofi: Annual General Meeting of April 30, 2019
Download the PDF version
2019-04-27MMMM DD YYYY
Press releases
Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
Download the PDF version
2019-04-26MMMM DD YYYY
Press releases
ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes
Download the PDF version
2019-04-26MMMM DD YYYY
Press releases
CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
Download the PDF version
2019-04-26MMMM DD YYYY
Press releases
Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
Download the PDF version
2019-04-08MMMM DD YYYY
Press releases
Sanofi: Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
Download the PDF version
2019-04-01MMMM DD YYYY
Press releases
Sanofi: Availability of the Pre-quarterly Results Communication
Download the PDF version
2019-03-22MMMM DD YYYY
Press releases
Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin)
Download the PDF version
2019-03-15MMMM DD YYYY
Press releases
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Download the PDF version
2019-03-13MMMM DD YYYY
Press releases
Sanofi successfully prices EUR 2 billion of bond issues
Download the PDF version
2019-03-08MMMM DD YYYY
Press releases
Sanofi: Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report
Download the PDF version
2019-03-08MMMM DD YYYY
Press releases
Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
Download the PDF version
2019-03-01MMMM DD YYYY
Press releases
Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication
Download the PDF version
2019-03-01MMMM DD YYYY
Press releases
Sanofi : CHMP recommends ZynquistaTM (sotagliflozin) for the treatment of adults with type 1 diabetes
Download the PDF version
2019-02-25MMMM DD YYYY
Press releases
Sanofi : Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies
Download the PDF version
2019-02-25MMMM DD YYYY
Press releases
Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
Download the PDF version
2019-02-12MMMM DD YYYY
Press releases
Sanofi appoints Ameet Nathwani Chief Digital Officer
Download the PDF version
2019-02-07MMMM DD YYYY
Press releases
Sanofi delivers 2018 business EPS growth of 5.1% at CER
Download the PDF version
2019-02-06MMMM DD YYYY
Press releases
Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director
Download the PDF version
2019-02-06MMMM DD YYYY
Press releases
Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Download the PDF version
2019-02-05MMMM DD YYYY
Press releases
Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
Download the PDF version
2019-02-04MMMM DD YYYY
Press releases
Sanofi : CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
Download the PDF version
2019-01-30MMMM DD YYYY
Press releases
Sanofi: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo
Download the PDF version
2019-01-18MMMM DD YYYY
Press releases
Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes
Download the PDF version
2019-01-11MMMM DD YYYY
Press releases
Sanofi: Availability of the Pre-quarterly Results Communication
Download the PDF version
2019-01-09MMMM DD YYYY
Press releases
New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder
Download the PDF version
2019-01-07MMMM DD YYYY
Press releases
Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

Follow us

Sanofi on Twitter
Sanofi TV on YouTube
Sanofi On LinkedIn
Sanofi on Instagram
Sanofi RSS feeds

© Sanofi 2004-2019 - All rights reserved

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies

OK